Form 4: Apellis CEO Exercises Stock Options, Boosts Direct Stake

Apellis Pharmaceuticals CEO Cedric Francois exercised 8,840 stock options at $3.76 per share, increasing his direct beneficial ownership.

Summary

• Cedric Francois, Chief Executive Officer and Director of Apellis Pharmaceuticals, Inc. (APLS), exercised 8,840 stock options on February 3, 2026.
• The exercise price for these options was $3.76 per share.
• Following this transaction, Mr. Francois directly owns 490,837 shares of Apellis Pharmaceuticals common stock.
• He also indirectly holds shares through several trusts: The Cedric Francois Irrevocable Trust of 2023 2 (307,946 shares), The Cedric Francois Irrevocable Trust of 2023 (472,065 shares), The Francois Grossi Trust (300,000 shares), and The Francois-DuBois Educational Trust (234,411 shares).
• The exercised option was originally granted on February 8, 2016, and was fully vested prior to exercise.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as an insider exercising options indicates confidence in the company's value and a realization of long-term compensation, which can be interpreted favorably by the market.

Positives

• CEO Cedric Francois increased his direct beneficial ownership in Apellis Pharmaceuticals by exercising stock options, signaling continued alignment with shareholder interests.
• The exercise of fully vested options indicates a realization of value from long-term incentive compensation.

Future Outlook

This Form 4 filing is a transactional report and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, such as the exercise of stock options, are a standard component of executive compensation in the biotechnology and pharmaceutical sectors. These transactions align executive incentives with long-term company performance and are routinely disclosed to ensure market transparency.

Comparison to Industry Standards

• Insider option exercises are a common and accepted practice for executive compensation across publicly traded companies, particularly in growth-oriented industries like biotech.
• The exercise price of $3.76 for an option granted in 2016 suggests that the company's stock price has likely appreciated significantly since the grant date, indicating a successful long-term incentive for the executive, comparable to similar programs at peer companies.

Related Party Transactions

• Cedric Francois indirectly holds shares through The Francois Grossi Trust, for which his spouse, Juliana Grossi, serves as trustee. He disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: Provides transparency into insider holdings and transactions, which can influence investor sentiment and perceptions of management's confidence.
• Management: Reflects the realization of value from long-term incentive compensation plans, aligning executive interests with company performance.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction (option exercise) by the CEO. While it demonstrates the CEO realizing value from long-term incentives and increasing direct ownership, it does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change from a 'hold' position based solely on this filing. It is a neutral to slightly positive signal, but not sufficient to alter a broader investment thesis.

Keywords

Apellis Pharmaceuticals, APLS, Cedric Francois, Stock Options, Insider Transaction, Form 4, CEO, Beneficial Ownership